Overexpression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: Resemblance to pathogenetic changes in Parkinson's disease

Journal of Neurochemistry

Volumn 91, Issue 2, 2004, Pages 451-461

  Yamada, Masanori ^a   Iwatsubo, Takeshi ^b   Mizuno, Yoshikuni ^a,c   Mochizuki, Hideki ^a,c  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

synuclein; Caspase 9; Parkinson's disease; Phospho synuclein; Recombinant adeno associated viral vector

Indexed keywords

ALPHA SYNUCLEIN; CASPASE 9; PARVOVIRUS VECTOR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DEMENTIA; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; GENE TRANSFER; LEWY BODY; MALE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SUBSTANTIA NIGRA; VIRUS RECOMBINANT;

ALPHA-SYNUCLEIN; ANIMALS; CASPASE 9; CASPASES; CELL LINE; DISEASE MODELS, ANIMAL; DOPAMINE; ENZYME ACTIVATION; GENE EXPRESSION; GENE TARGETING; GENES, REPORTER; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODY DISEASE; MACROMOLECULAR SUBSTANCES; MALE; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; SYNUCLEINS;

ANIMALIA; MUS MUSCULUS; PARVOVIRUS;

EID: 5444249974     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02728.x     Document Type: Article

References (52)

1. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571-576.
2. Dauer W. and Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
3. Dauer W., Kholodilov N., Vila M. et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 14524-14529.
4. Dawson T. M. and Dawson V. L. (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
5. Dong Z., Ferger B., Feldon J. and Bueler H. (2002) Overexpression of Parkinson's disease-associated alpha-synuclein A53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 53, 1-10.
6. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. and Iwatsubo T. (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160-164.
7. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q. and Lee V. M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521-533.
8. Gispert S., Del Turco D., Garrett L. et al. (2003) Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 24, 419-429.
9. Goers J., Manning-Bog A. B., McCormack A. L., Millett I. S., Doniach S., Di Monte D. A., Uversky V. N. and Fink A. L. (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 8465-8471.
10. Goldberg M. S. and Lansbury P. T. Jr (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, E115-E119.
11. Han B. S., Hong H. S., Choi W. S., Markelonis G. J., Oh T. H. and Oh Y. J. (2003) Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J. Neurosci. 23, 5069-5078.
12. Hasegawa M., Fujiwara H., Nonaka T., Wakabayashi K., Takahashi H., Lee V. M., Trojanowski J. Q., Mann D. and Iwatsubo T. (2002) Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277, 49071-49076.
13. Hashimoto M., Rockenstein E. and Masliah E. (2003) Transgenic models of alpha-synuclein pathology: past, present, and future. Ann. NY Acad. Sci. 991, 171-188.
14. Hattori N., Tanaka M., Ozawa T. and Mizuno Y. (1991) Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30, 563-571.
15. Hsu L. J., Sagara Y, Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M. and Masliah E. (2000) Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410.
16. Hunot S. and Hirsch E. C. (2003) Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 53, S49-S58; discussion S58-S60.
17. Kahle P. J., Neumann M., Ozmen L. et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373.
18. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J. and Bjorklund A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791.
19. Kirik D., Annett L. E., Burger C., Muzyczka N., Mandel R. J. and Bjorklund A. (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 2884-2889.
20. Klein R. L., King M. A., Hamby M. E. and Meyer E. M. (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum. Gene Ther. 13, 605-612.
21. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B. and Baekelandt V. (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 13, 364-372.
22. Lee M. K., Stirling W., Xu Y, Xu X., Qui D., Mandir A. S., Dawson T. M., Copeland N. G., Jenkins N. A. and Price D. L. (2002) Human alpha-synuclein- harbouring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA 99, 8968-8973.
23. Lo Bianco C, Ridet J. L., Schneider B. L., Deglon N. and Aebischer P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA 99, 10813-10818.
24. Lucking C. B. and Brice A. (2000) Alpha-synuclein and Parkinson's disease. Cell. Mol. Life Sci. 57, 1894-1908.
25. Maries E., Dass B., Collier T. J., Kordower J. H. and Steece-Collier K. (2003) The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4, 727-738.
26. Maroteaux L. and Scheller R. H. (1991) The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11, 335-343.
27. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
28. Matsuoka Y., Vila M., Lincoln S. et al. (2001) Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8, 535-539.
29. Mizuno Y, Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T. and Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455.
30. Mizuno Y, Matuda S., Yoshino H., Mori H., Hattori N. and Ikebe S. (1994) An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35, 204-210.
31. Mochizuki H., Hayakawa H., Migita M. et al. (2001) An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 10918-10923.
32. Neumann M., Kahle P. J., Giasson B. I. et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 1429-1439.
33. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., Meijer L., Kahle P. J. and Haass C. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390-397.
34. Outeiro T. F. and Lindquist S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772-1775.
35. Paxinos G. and Watson C. (1998) The rat brain, in Stereotaxic Coordinates (Paxinos G. and Watson C., eds), pp. 38-45, 4th Edn. Academic Press, New York.
36. Perrin R. J., Woods W. S., Clayton D. F. and George J. M. (2000) Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34393-34398.
37. Pronin A. N., Morris A. J., Surguchov A. and Benovic J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275, 26515-26522.
38. van der Putten H., Wiederhold K. H., Probst A. et al. (2000) Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20, 6021-6029.
39. Raisler B. J., Berns K. I., Grant M. B., Beliaev D. and Hauswirth W. W. (2002) Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc. Natl Acad. Sci. USA 99, 8909-8914.
40. Richfield E. K., Thiruchelvam M. J., Cory-slechta D. A., Wuertzer C., Gainetdinov R. R., Caron M. G., Di Monte D. A. and Federoff H. J. (2002) Behavioural and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175, 35-48
41. Rockenstein E., Mallory, M., Hashimoto M., Song D., Shults C. W., Lang I. and Masliah E. (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68, 568-578.
42. Saito Y, Kawashima A., Ruberu N. N. et al. (2003) Accumulation of phosphorylated alpha-synuclein in ageing human brain. J. Neuropathol. Exp. Neurol. 62, 644-654.
43. Schwarting R. K. and Huston J. P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275-331.
44. Singleton A. B., Fairer M., Johnson J. et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
45. Spillantini M, G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839-840.
46. Takahashi M., Kanuka H., Fujiwara H., Koyama A., Hasegawa M., Miura M. and Iwatsubo T. (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci. Lett. 336, 155-158.
47. Tanaka Y., Engelender S., Igarashi S., Rao R. K., Wanner T., Tanzi R. E., Sawa A. V. L. D., Dawson T. M. and Ross C. A. (2001) Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919-926.
48. Tanaka M., Kim Y. M., Lee G., Junn E., Iwatsubo T. and Mouradian M. M. (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625-4631.
49. Ungerstedt U. and Arbuthnott G. (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493.
50. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F. F., Yantiri F., Yang L., Beal M. F. and Andersen J. K. (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 21, 9519-9528.
51. Wang X. (2001) The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933.
52. Warner T. T. and Schapira A. H. (2003) Genetic and environmental factors in the cause of Parkinson's disease. Ann. Neurol. 53, S16-S23; discussion S23-S25.